Clinical Trial Update: Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line Doxorubicin and Trabectedin in metastatic leiomyosarcoma has completed; results are not detailed in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma
• Soft Tissue Leiomyosarcoma
• Uterine Leiomyosarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• Trabectedin (trabectedin)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Uterus Leiomyosarcoma, Soft Tissue Leiomyosarcoma | Phase 2 | Status: COMPLETED